ArticleAmerican journal of clinical dermatology2020
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.
Article in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- S3 guideline diagnostics and therapy of alopecia areata - Part 1: Diagnostics and epidemiology.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).American journal of clinical dermatology · 2023Trial
- Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2.Dermatology and therapy · 2026Article
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach.Dermatology and therapy · 2026Article
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.American journal of clinical dermatology · 2026Observational
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study.Clinical drug investigation · 2026Article
- Ophthalmologic Comorbidities in Alopecia Areata.Journal of clinical medicine · 2025Review
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Assessment of Alopecia Areata Disease Severity in Pediatric Patients.Pediatric dermatology · 2025Review
- Survey on Alopecia Areata Patients' Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study.Annals of dermatology · 2024Article
- Trichoscopy For Eyelash Involvement in Lichen Planopilaris: A Pilot Prospective Study.Dermatology practical & conceptual · 2024Article
- Assessment and Validity of Trichoscopy for Eyebrow Involvement in Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case-Control Study.Dermatology practical & conceptual · 2024Article
- Korean Consensus Criteria for the Severity Classification of Alopecia Areata.Annals of dermatology · 2024Article
- Alopecia Areata of the Nails: Diagnosis and Management.Journal of clinical medicine · 2024Review
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey.Clinical, cosmetic and investigational dermatology · 2024Article
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.Dermatology and therapy · 2023Article
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023).Dermatology and therapy · 2023Review
- The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata.Dermatology and therapy · 2023Article
- Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundEyebrow and eyelash hair loss and nail damage-in addition to scalp hair loss-are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials.
objectivesOur objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, eyelash and nail signs/symptoms.
methodsIterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed.
resultsDermatologists (n = 10) described eyebrow and eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15-72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21-54 years) participated in the development of the eyebrow, eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters.
conclusionsThe ClinRO and PRO measures for eyebrow, eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.